KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBIT: 2009-2024

Historic EBIT for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to -$176.9 million.

  • Alnylam Pharmaceuticals' EBIT rose 578.49% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.7 million, marking a year-over-year increase of 240.70%. This contributed to the annual value of -$176.9 million for FY2024, which is 37.31% up from last year.
  • Alnylam Pharmaceuticals' EBIT amounted to -$176.9 million in FY2024, which was up 37.31% from -$282.2 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year EBIT high stood at -$176.9 million for FY2024, and its period low was -$828.4 million during FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median EBIT value was -$282.2 million (recorded in 2023), while the average stood at -$414.7 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' EBIT declined by 10.78% in 2022 and then spiked by 64.06% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBIT (Yearly) stood at -$828.4 million in 2020, then rose by 14.46% to -$708.7 million in 2021, then dropped by 10.78% to -$785.1 million in 2022, then soared by 64.06% to -$282.2 million in 2023, then soared by 37.31% to -$176.9 million in 2024.